Navigation Links
Alfacell Provides ONCONASE(R) NDA Submission Update
Date:12/5/2008

SOMERSET, N.J., Dec. 5 /PRNewswire-FirstCall/ -- Alfacell Corporation (Nasdaq: ACEL) today reported that the U.S. Food and Drug Administration (FDA) has scheduled a pre-NDA meeting date at the end of January 2009 for discussion of the company's planned submission of the final components of the ONCONASE rolling New Drug Application (NDA) for the treatment of unresectable malignant mesothelioma (UMM) patients. The pre-NDA meeting is an important step to complete prior to the planned submission of the final components of the ONCONASE rolling NDA for patients that have failed prior chemotherapy. Therefore, the final components of the rolling ONCONASE NDA will not be finalized until Alfacell receives guidance from the FDA at the pre-NDA meeting. Alfacell expects to provide an update on the planned completion of the rolling NDA within 48 hours of the conclusion of the pre-NDA meeting.

As the company has previously reported, the results of the preliminary statistical analysis of the data from the confirmatory Phase IIIb clinical trial for ONCONASE in patients suffering from UMM did not meet statistical significance for the primary endpoint of survival in UMM. However, a statistically significant improvement in survival was seen in the treatment of UMM patients who failed one prior chemotherapy regimen, a pre-defined primary data set for this sub-group of patients in the trial, which represents a currently unmet medical need.

Since receiving the results of this preliminary statistical analysis in late May 2008, the company engaged in an extensive and careful review of the data to submit to the FDA prior to the pre-NDA meeting. While preparations of materials for the pre-NDA meeting have taken more time than expected, by submitting the pre-NDA meeting request on October 3, 2008, Alfacell had anticipated that the pre-NDA meeting wo
'/>"/>

SOURCE Alfacell Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Paper in Molecular Cancer Therapeutics Reports that a Novel Combination of Alfacells ONCONASE(R) and Rosiglitazone Induces a Synergistic Apoptotic Effect in Several Cancer Cell Lines
2. Alfacell Announces ONCONASE(R) Distribution and Marketing Agreement with Megapharm for Israel
3. Alfacell Corporation Announces Preliminary Results From ONCONASE(R) Phase IIIb Clinical Trial
4. Alfacells ONCONASE(R) Shows Potential as Radiation Sensitizer for Lung Cancer Treatment
5. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
6. Alfacell Reports Financial Results for First Quarter of Fiscal 2008
7. Alfacell Corporation to Present at UBS Global Life Sciences Conference
8. Alfacell Updates Status of ONCONASE(R) Phase III Clinical Program
9. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
10. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
11. Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , Sept. 19, 2014  CytRx Corporation (Nasdaq: ... specializing in oncology, today announced that David J. ... BioCentury,s 2014 NewsMakers in the Biotech Industry Conference on Friday, ... The conference will take place at the Millennium Broadway ... A live and archived webcast of the ...
(Date:9/19/2014)... -- Reductions in kidney failure obtained during ... with diabetes type 2 "Intensive treatment is ... kidneys." Australian researchers have discovered that intensive ... to persistent reductions in kidney failure many years after ... has found that, five and a half years after ...
(Date:9/18/2014)... September 19, 2014 ... http://www.researchandmarkets.com/research/qqjrnh/global_molecular ) has announced the addition of ... report to their offering. ... the study of chromosomes using molecular biology ... genes and chromosomes. It plays a crucial ...
Breaking Medicine Technology:CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 2CytRx to Present at BioCentury's 2014 NewsMakers in the Biotech Industry Conference 3ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 2ADVANCE-ON Post-trial Observational Study: Blood Pressure Arm and Glucose Arm Results 3Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 2Global Molecular Cytogenetics Market 2014-2018: Key Vendors are Abbott, Affymetrix, Agilent Technologies, F. Hoffmann-La Roche, Illumina and PerkinElmer 3
... /PRNewswire-Asia-FirstCall/ -- China Botanic Pharmaceutical Inc. (NYSE AMEX: ... "Company"), a developer, manufacturer and distributor of botanical ... China, today announced that the Company,s Badger Oil, ... Pharmaceutical Co., Ltd ("Renhuang"), has achieved sales of ...
... Alison MacNeil issued the following statements today regarding ... PBS this week: "When I vaccinated ... are not required to test the safety of vaccines ... thousands of parents with Autistic children report that, like ...
Cached Medicine Technology:China Botanic Pharmaceutical Provides Update on Badger Oil Sales 2China Botanic Pharmaceutical Provides Update on Badger Oil Sales 3Daughter of Journalist Robert MacNeil States that Son Regressed Into Autism After Vaccines 2
(Date:9/19/2014)... Red Bank, NJ (PRWEB) September 19, 2014 ... Jersey’s largest not-for-profit provider of home health care, hospice ... join Deutsche Bank to ring the Opening Bell yesterday ... 1912 by a New Jersey philanthropist and social entrepreneur ... other diseases, VNA Health Group has always worked to ...
(Date:9/19/2014)... (PRWEB) September 19, 2014 Boston Scientific ... mesh lawsuit ( http://www.transvaginalmeshlawsuithelp.com/ ) that is scheduled ... month, Bernstein Liebhard LLP reports. According to ... Court, the company asserts that claims involving its Solyx ... Practice and Remedies Code, a section of which shields ...
(Date:9/19/2014)... Sept. 19, 2014 (HealthDay News) -- Your brain structure could ... a new study suggests. Researchers at Yale University found ... known as the parietal cortex may be more likely to ... this area. , , The study, funded by the U.S. ... men and women living in the Northeast. The researchers sought ...
(Date:9/19/2014)... News) -- Although there is mounting evidence that ... and older adults in the United States don,t ... new research. Less than one-quarter of adults ... the Department of Health and Human Services, the ... promoting health and fitness and staying independent, researchers ...
(Date:9/19/2014)... HealthDay Reporter THURSDAY, ... by stress and family conflicts before surgery may face ... new study suggests. Investigators found that patients with ... three times greater risk for complications compared to those ... "We,ve long known that patient quality of life is ...
Breaking Medicine News(10 mins):Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 2Health News:NJ Largest Home Healthcare Not-for-Profit Joins Deutsche Bank to Ring NYSE Opening Bell 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 2Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 3Health News:Transvaginal Mesh Lawsuit Defendant Moves For Summary Judgment in Case Scheduled for Upcoming Texas Trial, Bernstein Liebhard LLP Reports 4Health News:Brain Structure Might Help Predict Risky Behavior 2Health News:Adults Over 45 Not Meeting U.S. Muscle Strengthening Guidelines, Study Says 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 2Health News:Family Squabbles Can Derail Recovery From Cancer Surgery 3
... WASHINGTON, June 3 AGA Medical Corporation,(AGA), a ... a $2,million criminal penalty in connection with corrupt ... Foreign Corrupt Practices Act,(FCPA), Acting Assistant Attorney General ... a deferred prosecution agreement with AGA,and filed a ...
... issued under second round of Critical Challenges in,Parkinson,s ... The Michael J. Fox,Foundation for Parkinson,s Research is ... non-invasive imaging technologies that would allow,scientists to visualize ... living brain. Such techniques hold potential to,serve as ...
... Million; 57% Increase ... - Record Fourth Quarter U.S. Sales of $2.1 Million; 198% Increase ... Year-Over-Year - ... to be Held Today at 3:30 pm Central Time -, MINNEAPOLIS, June 3 Uroplasty, Inc. ...
... Statistical survey indicates doctors need to be more clear ... News) -- For reasons not easily understood, many patients ... will live longer than their doctors tell them they ... Duke University began telling people being treated for heart ...
... No weight gain seen among those who drink 100% juice, ... 3 (HealthDay News) -- Children who drink 100 percent fruit ... enjoy more nutritious diets than kids who don,t drink the ... was not excessive among children," said lead researcher Theresa A. ...
... the University of Minnesota and University of Minnesota Children,s ... for a young boy,s fatal genetic skin disease, recessive ... and bone marrow transplant. Nate Liao, a 25-month-old from ... , "We have established a new standard of ...
Cached Medicine News:Health News:AGA Medical Corporation Agrees to Pay $2 Million Penalty and Enter Deferred Prosecution Agreement for FCPA Violations 2Health News:Michael J. Fox Foundation for Parkinson's Research Commits up to $2 million to Visualize Alpha-Synuclein Protein in the Brain 2Health News:Michael J. Fox Foundation for Parkinson's Research Commits up to $2 million to Visualize Alpha-Synuclein Protein in the Brain 3Health News:Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008 2Health News:Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008 3Health News:Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008 4Health News:Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008 5Health News:Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008 6Health News:Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008 7Health News:Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008 8Health News:Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008 9Health News:Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008 10Health News:Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008 11Health News:Uroplasty Reports Record Growth for the Fourth Quarter and Fiscal Year 2008 12Health News:Heart Failure Patients Overestimate Their Life Expectancy 2Health News:Heart Failure Patients Overestimate Their Life Expectancy 3Health News:Fruit Juice May Be Healthy for Kids: Study 2Health News:Fruit Juice May Be Healthy for Kids: Study 3Health News:U of M sets course for cure of fatal childhood skin disease 2
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
Our 3.5v Streak or Spot Retinoscope Sets feature instruments with the brightest light output in the industry, reliable handles, and convenient cases....
... Indirect Ophthalmoscope Power Source provides power to ... ophthalmic instruments. The versatile wall/desk power source ... or on the side of a desk ... portable power pack provides power no matter ...
The Welch Allyn 125 BIO is designed to achieve precise binocular viewing and stereopsis easier than ever before. Its observation paths can be adjusted from 48 mm to 74 mm to handle the widest and nar...
Medicine Products: